GNMX - ETF AI Analysis
Top Page
Corgi Genomics & Precision Medicine ETF (GNMX)
Rating:60Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and in recent months, showing solid momentum in its niche area.
Leading Health Care Innovators
Top holdings like Thermo Fisher, Moderna, and Vertex Pharmaceuticals have shown strong or steady performance, helping drive the fund’s returns.
Focused Exposure to Genomics and Precision Medicine
A high allocation to health care and genomics-related companies gives investors targeted exposure to a growing medical innovation theme.
Negative Factors
High Sector Concentration
With most assets in health care, the ETF is heavily exposed to swings in one industry rather than being broadly diversified.
Small Fund Size
The relatively low assets under management may lead to higher trading costs or a greater risk the fund could be closed if it does not grow.
Single-Country Focus
Because the ETF is almost entirely invested in U.S. companies, investors get limited diversification across different global markets.
GNMX vs. SPDR S&P 500 ETF (SPY)
AUM2.75M
RegionGlobal
Expense Ratio0.35%
Beta0.44
IssuerCorgi
Inception DateMay 06, 2026
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume281
30 Day Avg. Volume1,043
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
43.60Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering58
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GNMX Summary
The Corgi Genomics & Precision Medicine ETF (GNMX) is a healthcare-focused fund that invests in companies using DNA and data to develop new tests and treatments. It follows a genomics and precision medicine theme rather than a broad market index, holding firms involved in gene editing, cancer therapies, and advanced diagnostics. Well-known names in the fund include Thermo Fisher and Moderna. Someone might invest in GNMX for long-term growth and to tap into cutting-edge medical innovation. However, because it is heavily focused on genomics and biotech, its price can be very volatile and may swing more than the overall market.
How much will it cost me?This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. That’s higher than the cost of a typical broad, passively managed index ETF because this is a specialized, actively managed fund focused on genomics and precision medicine companies.
What would affect this ETF?This genomics and precision medicine ETF could benefit if new DNA-based tests and targeted treatments from companies like Thermo Fisher, Vertex, and Moderna gain wider medical acceptance, if healthcare systems increase spending on advanced diagnostics, and if supportive drug-approval policies encourage innovation globally. On the other hand, it could be hurt by tighter drug pricing rules, clinical trial setbacks at smaller biotech holdings, shifts in healthcare budgets away from high-cost therapies, or market pullbacks that hit high-growth health care stocks especially hard.
GNMX Top 10 Holdings
GNMX is leaning hard into cutting-edge health care, with a clear tilt toward U.S.-listed genomics and precision-medicine names. Thermo Fisher and Illumina are steady climbers, providing a solid backbone through their lab tools and sequencing platforms, while Moderna has been a standout riser, giving the fund some extra spark despite its choppy fundamentals. On the flip side, Revolution Medicines and Alnylam look more like speed bumps, with weaker recent trends. Overall, the ETF is concentrated in biotech and genomic platforms, not broad, defensive health care.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Thermo Fisher | 8.87% | $233.43K | $239.76B | 36.84% | 72 Outperform | |
| Moderna | 6.89% | $181.30K | $58.14B | 521.10% | 59 Neutral | |
| Vertex Pharmaceuticals | 6.14% | $161.68K | $130.09B | 33.38% | 78 Outperform | |
| Illumina | 4.30% | $113.32K | $34.57B | 137.97% | 71 Outperform | |
| Guardant Health | 3.89% | $102.32K | $23.47B | 211.39% | 61 Neutral | |
| Revolution Medicines | 3.46% | $91.10K | $41.99B | 352.32% | 52 Neutral | |
| 10x Genomics | 3.35% | $88.31K | $9.47B | 480.03% | 60 Neutral | |
| Incyte | 2.98% | $78.59K | $25.29B | 48.40% | 81 Outperform | |
| Genmab | 2.98% | $78.43K | $20.30B | 23.16% | 76 Outperform | |
| Alnylam Pharma | 2.73% | $71.81K | $32.03B | -45.70% | 60 Neutral |
GNMX Technical Analysis
Positive
―
Price Trends
32.79
Positive
Market Momentum
0.75
Positive
63.99
Neutral
85.21
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GNMX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 35.35, equal to the 50-day MA of 32.79, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.75 indicates Positive momentum. The RSI at 63.99 is Neutral, neither overbought nor oversold. The STOCH value of 85.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNMX.
GNMX Peer Comparison
Comparison Results
Performance Comparison
GNMX
Corgi Genomics & Precision Medicine ETF
36.29
11.00
43.50%
FFND
Future Fund Active ETF
―
―
―
FITZ
Fitz-Gerald Must Have Portfolio ETF
―
―
―
IQM
Franklin Intelligent Machines ETF
―
―
―
HECO
SPDR Galaxy Hedged Digital Asset Ecosystem ETF
―
―
―
HELX
Franklin Genomic Advancements ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents